ESMO

Opdivo Plus Chemo Betters Survival in Urothelial Carcinoma

October 22nd 2023, 5:55pm

Article

Adding Opdivo to a standard-of-care chemotherapy regimen in patients with unresectable or metastatic urothelial carcinoma improved progression-free and overall survival.

Welireg Outperforms Afinitor in Advanced Clear Cell Kidney Cancer

October 22nd 2023, 1:00pm

Article

Welireg led to improved time to progression and objective response rates compared to Afinitor for patients with advanced clear cell renal cell carcinoma, according to study findings.

Firstline Retevmo Improves Survival Rates Without Disease Progression in Select Patients With Thyroid Cancer

October 21st 2023, 11:00pm

Article

Treatment with Retevmo, compared with Cabometyx or Caprelsa, improved progression-free survival and overall response rate in patients with advanced RET-mutant medullary thyroid cancer who were multikinase inhibitor-naïve.

Rybrevant Plus Chemo Offers Better Progression-Free Survival for NSCLC Subset

October 21st 2023, 10:00pm

Article

The treatment combination of Rybrevant plus chemotherapy offers better progression-free survival for patients with advanced EGFR exon 20 insertion-positive NSCLC.

Retevmo Improves Progression-Free Survival in Patients with RET-Fusion Positive NSCLC

October 21st 2023, 9:00pm

Article

Retevmo improved progression-free survival, compared with chemotherapy with or without Keytruda in patients with RET-fusion positive non-small cell lung cancer.

Alecensa Reduces Recurrence, Mortality Risk in Lung Cancer Subset

October 21st 2023, 8:00pm

Article

Patients with ALK-positive, early-stage non-small cell lung cancer obtained significant improvement in disease-free survival.

Tagrisso-Chemo Combo Reduces Progression Risk in EGFR-Positive NSCLC With Central Nervous System Metastases

October 21st 2023, 6:57pm

Article

Treating patients with Tagrisso, a tyrosine kinase inhibitor, plus chemotherapy reduced the progression risk of disease of the central nervous system in patients with EGFR-positive non-small cell lung cancer.

Patients With Resectable NSCLC See Benefits from Pre- and Post-Surgical Opdivo

October 21st 2023, 6:09pm

Article

Treatment with neoadjuvant Opdivo, followed by Opdivo after surgery led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small cell lung cancer.

Keytruda Plus Chemoradiotherapy Bests Standard of Care in Advanced Cervical Cancer

October 20th 2023, 11:00pm

Article

Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.

Senaparib Improves Progression-Free Survival in Advanced Ovarian Cancer

October 20th 2023, 10:00pm

Article

The phase 3 FLAMES trial showed a benefit of progression-free survival with senaparib compared to placebo in patients with newly diagnosed, advanced ovarian cancer.